The European Medicines Agency on Twitter

The European Medicines Agency have created a news feed on Twitter (https://twitter.com/EMA_News). However, some companies have chosen to block access to Twitter for employees. To help regulatory professionals in those companies, we render recent items from their news feed here, for accessibility.

EMA holds international workshop on clinical trials in the context of global medicines development: http://bit.ly/byTny9
European Medicines Agency holds first scientific workshop on nanomedicines: http://bit.ly/b3GuMc
CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix: http://bit.ly/aJQuI3
European Medicines Agency recommends restricting the use of modafinil: http://bit.ly/bNx1Mu
European Medicines Agency confirms positive benefit-risk balance of topical formulations of ketoprofen: http://bit.ly/bfvGYl
European Medicines Agency confirms positive benefit-risk balance of Rotarix: http://bit.ly/afdBMl
European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim: http://bit.ly/bSNX6v
European Medicines Agency starts review of rosiglitazone-containing medicines: http://bit.ly/cFu1Fd
Meeting highlights from the EMA CHMP Meeting June 21 - 24: http://www.ema.europa.eu/pdfs/human/press/pr/27209310en.pdf
EMA and European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) launch ‘ENCePP studies’ http://bit.ly/duGwKG
Check this video out -- Workshop on stem-cell based therapies http://youtu.be/SvwlXjyPaYo